Journal of Epidemiology and Public Health
Vol. 7 No. 3 (2022)

Effect of ACE Inhibitor Therapy on Mortality in COVID-19 Patients with Hypertension: Meta-Analysis

Zainal, Dwi Trisnawati (Unknown)



Article Info

Publish Date
16 Jul 2022

Abstract

Background: Acute respiratory syndrome Corona Virus 2 (SARS-CoV-2) can trigger the occurrence of respiratory infectious disease Coronavirus Disease 2019 (COVID-19). Patients who have comorbid health problems such as hypertension, chronic liver, cardiovascular and diabetes mellitus are more likely to experience deterioration and death. ACE inhibitor therapy in patients with hypertension has a therapeutic effect in lowering blood pressure and is able to reduce mortality rates in COVID-19 patients, but the benefits of ACE inhibitors in patients with COVID-19 are still uncertain. This study aims to determine how much influence ACE inhibitors have on COVID-19 patients with hypertension on mortality rates.Subjects and Method: This study is a systematic review and meta-analysis with the following PICO, population: COVID-19 patients with hypertension. Intervention: administration of ACE inhibitor therapy. Comparison: therapy other than ACE inhibitors. Outcome: mortality. The articles used in this study were obtained from several online databases, including Science Direct, PubMed and Google Scholar. The keywords used in the article search were: “ACE inhibitor” AND “COVID-19” AND “Hypertension” AND “mortality”. The articles included are full-text English with a cohort study design from 2020 to 2021 and report the odds ratio in multivariate analysis. The selection of articles was carried out using the PRISMA flow chart. The articles were analyzed using the Review Manager 5.4. application.Results: A total of 4 cohort studies involving 4,998 COVID-19 patients from America, China and Italy were selected for systematic review and meta-analysis. The data collected yielded information that COVID-19 patients with hypertension who were given ACE inhibitors reduced the risk of mortality 0.67 times compared to COVID-19 patients with hypertension who were not treated with ACE inhibitors (aOR= 0.67; 95% CI= 0.36 to 1.26; p= 0.210).Conclusion: ACE inhibitors can reduce the risk of mortality in COVID-19 patients with hypertension. Keywords: COVID-19, hypertension, ACE inhibitors, mortality. Correspondence:Dwi Trisnawati Zainal. Social Security Administrator for Health, Madiun, East Java. Jl. Timor 6 Madiun, East Java, Indonesia. Email: dwitrisnawatiz@gmail.com. Mobile: 081331282009.

Copyrights © 2022






Journal Info

Abbrev

jepublichealth

Publisher

Subject

Public Health

Description

Background: Increased blood pressure for a long time can increase the risk of kidney failure, co­ronary heart disease, brain damage, and other di­seases. In 2019, it is estimated that hyper­tens­ion is experienced by 1.13 billion people in the world with most (two thirds) living in low and ...